What Is Graft vs. Host Disease (GVHD)?
Updated: 2 days ago
Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026
Quick Answer: What is GVHD?
Graft-versus-host disease (GVHD) is a condition in which donor immune cells from a transplant attack the recipient's healthy tissues, because the donor's T-cells see the recipient's antigens as foreign [1]. Acute GVHD usually occurs within 100 days [1], while chronic GVHD appears later and often lasts longer. Treatment includes corticosteroids, targeted immunosuppressants and photopheresis [1] to calm the immune response.
What the research says
Ruxolitinib helped when steroids failed in acute GVHD. In REACH2, a randomized phase 3 trial of 309 patients with glucocorticoid-refractory acute GVHD, overall response at day 28 was 62% with ruxolitinib versus 39% with the investigator's choice of other therapies. Low platelet counts (thrombocytopenia) were more common with ruxolitinib (33% vs 18%) (Zeiser et al., The New England Journal of Medicine, 2020) [3].
It also helped in chronic GVHD. In REACH3, a randomized phase 3 trial of 329 patients with steroid-refractory or steroid-dependent chronic GVHD, overall response at week 24 was 49.7% with ruxolitinib versus 25.6% with control therapy, and median failure-free survival was longer (more than 18.6 months vs 5.7 months). The authors note chronic GVHD becomes glucocorticoid-refractory or -dependent in about 50% of patients (Zeiser et al., The New England Journal of Medicine, 2021) [4].
More options are arriving. A review reports that ibrutinib, belumosudil and ruxolitinib are approved for refractory chronic GVHD, and that abatacept, DPP-4 inhibition and post-transplant cyclophosphamide are promising prevention strategies that still need further evaluation (Inamoto et al., Blood Cell Therapy, 2021) [5].
Key Takeaways Table
Feature | Acute GVHD (aGvHD) | Chronic GVHD (cGvHD) |
Typical Onset | Within first 100 days post-transplant [1] | Typically after 100 days; most cases start within 2 years [1] |
Primary Organs | Skin, GI tract, Liver | Skin, Mouth, Eyes, Lungs, Liver, GI |
Skin Signs | Red, painful, or itchy rash | Thickening, tightness, or discoloration |
GI Symptoms | Severe diarrhea, nausea, vomiting [1] | Dry mouth, sores, difficulty swallowing |
Treatment | High-dose steroids, targeted drugs | Steroids, photopheresis, topical care |
Outlook | Often resolves with treatment | May require long-term management |
How does graft vs. host disease (GVHD) happen?
Graft vs. Host Disease represents a unique immunological challenge where the therapy itself—the life-saving transplant—triggers a defensive response against the patient. In an allogeneic transplant, the recipient receives stem cells from a donor. These cells eventually mature into a new immune system. However, if these new donor T-cells recognize the recipient's cells as "non-self," they initiate an inflammatory cascade [1].
This interaction is governed by Human Leukocyte Antigens (HLA) [1]. Even with a close match, minor differences can trigger the donor cells to attack. This "graft-versus-host" effect is the opposite of organ rejection, where the recipient's immune system attacks the new organ. In GVHD, the new immune system is the aggressor [1].
How is acute graft vs. host disease different from chronic GVHD?
Medical professionals distinguish between acute and chronic forms based on timing and clinical presentation. Acute GVHD typically manifests early in the recovery process [1], often as the new marrow begins to produce cells (engraftment). Chronic GVHD is more persistent and can mimic autoimmune disorders like lupus or scleroderma.
Organ System | Acute GVHD Symptoms | Chronic GVHD Symptoms |
Skin | Sunburn-like rash, itching | Leathery texture, thinning, pigment changes |
Liver | Jaundice, elevated enzymes | Jaundice, abdominal swelling |
GI Tract | Watery diarrhea, cramping | Dryness, strictures, malabsorption |
Eyes | Less common | Severe dryness, blurred vision, grit |
Mouth | Less common | White patches, sensitivity to spicy food |
What triggers graft vs. host disease, and who is at risk?
Not every transplant recipient develops GVHD. Several factors influence the likelihood and severity of the condition. The degree of HLA matching between the donor and recipient is the most significant predictor. A perfectly matched sibling donor carries the lowest risk, while unrelated or partially matched donors increase the probability [2].
Risk Factor | Impact on GVHD Risk |
HLA Match | Closer matches significantly reduce risk [1] |
Donor Type | Sibling donors are lower risk than unrelated donors [1] |
Patient Age | Older recipients may have a higher incidence [1] |
Stem Cell Source | Peripheral blood cells may have higher risk than bone marrow [1] |
Gender Mismatch | Female donors for male recipients can increase risk [1] |
How is graft vs. host disease diagnosed?
Diagnosing GVHD requires a combination of clinical observation and laboratory confirmation. Because symptoms can mimic infections or drug reactions, doctors often perform biopsies of the affected tissues to look for characteristic cellular changes under a microscope [1].
Physical Examination: Monitoring for rashes, jaundice, and GI distress.
Blood Panels: Checking liver function tests (bilirubin, alkaline phosphatase).
Biopsy: Taking small samples from the skin, stomach, or liver [1].
Imaging: CT scans or X-rays to assess organ involvement or rule out other issues.
Pulmonary Function Tests: Specifically for chronic GVHD affecting the lungs.
How is graft vs. host disease treated and managed?
The primary goal of GVHD treatment is to suppress the overactive donor immune cells without leaving the patient completely defenseless against infections. Treatment is often escalated based on the "grade" or severity of the symptoms [1] [2].
First-Line Therapy
Corticosteroids, such as prednisone or methylprednisolone, remain the standard starting point [1]. These drugs quickly dampen inflammation but require careful tapering to avoid side effects like bone loss or high blood sugar.
Second-Line and Targeted Therapy
If steroids are insufficient, doctors may use:
JAK Inhibitors: Drugs like ruxolitinib target specific signaling pathways in immune cells [1] [3].
Photopheresis (ECP): A process where blood is treated with light-sensitive chemicals and UV light before being returned to the body.
Monoclonal Antibodies: Targeted biological therapies that neutralize specific inflammatory proteins.
How can graft vs. host disease be prevented?
Preventing GVHD begins before the transplant. Doctors use "conditioning" regimens (chemotherapy or radiation) to prepare the host and prescribe prophylactic immunosuppressants like cyclosporine or methotrexate immediately following the infusion of donor cells.
Related Reading on Rinnit
Conclusion
Graft vs. Host Disease is a significant milestone in the transplant journey, requiring vigilant monitoring and a multidisciplinary care team. While the diagnosis can be daunting, the rapid evolution of targeted therapies and improved donor matching techniques have made GVHD more manageable than ever before. Patients are encouraged to report any new skin, GI, or eye changes immediately to ensure early intervention.
FAQ: Frequently Asked Questions
What is GVHD?
It is an immune response where donor cells attack the recipient's body.
Is GVHD contagious?
No, it is an internal immune reaction.
Can I get GVHD from a blood transfusion?
It is extremely rare but possible; blood products are usually irradiated to prevent this.
How soon does acute GVHD start?
Usually within the first 100 days post-transplant.
What does a GVHD rash look like?
It often looks like a sunburn and may be itchy or painful.
Can GVHD be cured?
Many cases resolve with treatment, though some chronic forms require long-term management.
Does everyone who gets a transplant get GVHD?
No. Roughly 30% to 70% of allogeneic transplant recipients develop acute GVHD, and about 40% to 50% develop chronic GVHD.
What is the difference between acute and chronic GVHD?
Acute is early and inflammatory; chronic is later and often resembles autoimmune disease.
Why is the liver affected?
Donor cells attack the bile ducts, causing jaundice.
What is "graft-versus-leukemia"?
A beneficial effect where donor cells attack remaining cancer cells.
Can GVHD affect the eyes?
Yes, chronic GVHD often causes severe dry eyes.
What is photopheresis?
A treatment using UV light to calm immune cells in the blood.
Are steroids the only treatment?
No, but they are the most common first-line therapy.
Does a perfect HLA match guarantee no GVHD?
No, but it significantly lowers the risk.
Can GVHD return after it's treated?
Yes, flares can occur, especially when tapering medications.
What is "engraftment"?
When the new donor cells start growing and making blood cells.
Can GVHD cause weight loss?
Yes, due to GI issues and decreased appetite.
Is GVHD life-threatening?
Severe (Grade III or IV) cases can be life-threatening.
What is a biopsy?
A procedure to take a tissue sample for microscopic analysis.
Can GVHD affect the lungs?
Yes, chronic GVHD can cause bronchiolitis obliterans.
Why do I need to take cyclosporine?
To prevent the donor cells from attacking your body.
What are the side effects of prednisone?
Mood changes, weight gain, high blood sugar, and increased infection risk.
Can GVHD affect the mouth?
Yes, causing sores and severe dryness.
Is there a diet for GVHD?
A low-microbial or GI-friendly diet may be recommended during flares.
Can children get GVHD?
Yes, anyone receiving an allogeneic transplant is at risk.
What is an allogeneic transplant?
A transplant using cells from a donor rather than the patient's own cells.
What is an autologous transplant?
Using your own cells; this does not cause GVHD.
Can GVHD affect the genitals?
Yes, chronic GVHD can cause scarring and dryness.
What is HLA?
Human Leukocyte Antigen, the protein markers used to match donors.
How long does chronic GVHD last?
It varies; some manage it for years, others see it resolve.
What is a "flare"?
A sudden worsening of symptoms.
Can stress trigger GVHD?
Stress doesn't cause it, but it can affect overall health and recovery.
What is Ruxolitinib?
A targeted JAK inhibitor used for steroid-refractory GVHD.
Why is my skin thickening?
This is a symptom of chronic GVHD (sclerotic skin changes), which can resemble scleroderma.
Can GVHD cause hair loss?
Chronic GVHD can affect hair follicles.
Do I need to wear sunscreen?
Yes, sun exposure can trigger or worsen skin GVHD.
What is bilirubin?
A yellow pigment made when old red blood cells break down; levels rise when the liver or bile ducts are damaged.
Can GVHD cause joint pain?
Yes, chronic GVHD can cause inflammation in the joints.
Is GVHD the same as organ rejection?
No, it's the "reverse"—the new cells attack the body.
What is a "mismatched" donor?
A donor whose HLA markers don't perfectly align with the recipient.
Can I exercise with GVHD?
Gentle exercise is usually encouraged as tolerated.
What is the 100-day mark?
A traditional milestone for distinguishing acute from chronic GVHD.
Can GVHD affect the nails?
Yes, chronic GVHD can cause ridges or loss of nails.
Why am I so tired?
Fatigue is a common symptom of the body fighting GVHD.
What is a BMT coordinator?
A nurse who helps manage your care and transplant schedule.
Can I get GVHD after a kidney transplant?
GVHD is very rare after solid-organ transplants such as a kidney; the more common problem there is organ rejection.
What are T-cells?
A type of white blood cell responsible for the GVHD attack.
Can GVHD be prevented?
Prophylactic meds and good donor matching help prevent many cases.
What is a GI consult?
A meeting with a stomach/intestine specialist to manage GI symptoms.
How often will I be tested?
Testing is frequent in the first year, often weekly or bi-weekly.
Helpful External Resources
References
Cleveland Clinic. Graft vs. Host Disease (GvHD). Cleveland Clinic. Last updated February 21, 2023. https://my.clevelandclinic.org/health/diseases/10255-graft-vs-host-disease-an-overview-in-bone-marrow-transplant
Blood Cancer United (formerly the Leukemia & Lymphoma Society). Graft-versus-host disease (GVHD). Blood Cancer United. Accessed October 15, 2026. https://bloodcancerunited.org/blood-cancer-care/adults/types-blood-cancer-treatment/stem-cell-transplantation/allogeneic/graft-versus-host-disease-gvhd
Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. The New England Journal of Medicine. 2020;382(19):1800-1810. PMID 32320566. https://doi.org/10.1056/NEJMoa1917635
Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. The New England Journal of Medicine. 2021;385(3):228-238. PMID 34260836. https://doi.org/10.1056/NEJMoa2033122
Inamoto Y, Zeiser R, Chan GC. Novel Treatment for Graft-versus-Host Disease. Blood Cell Therapy. 2021;4(4):101-109. PMID 36714067. https://doi.org/10.31547/bct-2021-022
Disclaimer
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding a medical condition or treatment.
Comments